KUALA LUMPUR: Novo Nordisk, a global health care company in diabetes care, today announced the launch of Ryzodeg in Malaysia.
Ryzodeg is a co-formulation insulin treatment with two type of distinct insulins, degludec and aspart, for controlling glucose levels which consists of a ratio of 70:30.
“Only 20 per cent of the patients receive primary care in Malaysia manage to keep their blood glucose level under control. If unmanaged serious complication will occur such as cardiovascular diseases, damage to nerves and kidney failure,” said Dr Zanariah Hussein, Consultant Endocrinologist at Hospital Putrajaya in her speech during the product launch held at Aloft Hotel.
University Malaya Medical Centre Associate Professor and Consultant Endocrinologist Prof Dr Alex Tan said current treatment options provide effective control but vary in terms of hypoglycaemia risk, resuspension, inflexible regiment and using multiple devices in some patients.
In contrast, he said the new product allowed the co-formulation without resuspension and provided 24-hour coverage which results in better fasting plasma glucose and better control for one or two meal-related glucose excursions.
Consultant Endocrinologist Dr Chan Siew Pheng said Ryzodeg was now available in the market, and the simple and smart diabetes treatment would enable more effective diabetes care and management.
“Ryzodeg provides patients with a more innovative treatment to improve their everyday life. This prescription-based insulin can be delivered as once-daily or twice daily injections in a new prefilled insulin pen called FlexTouch with no need for resuspension, providing Malaysians smart alternative means,” she said.
Present was Novo Nordisk Malaysia, Singapore, Brunei Vice-President and General Manager Richard Abela.
Diabetes is a major health concern in Malaysia. The nationwide prevalence of type 2 diabetes has escalated and posed a significant challenge for adults above the age of 30, affecting million of individuals.
In fact, diabetes-related death has reached 3.09 per cent (4,268) out of the total national mortality in 2017.
People living with diabetes face challenges managing their daily commitment as well as the treatment provided for them.
Malaysians living with diabetes should be equipped with tools to effectively manage high blood glucose level.